Haleon Pakistan Ltd. (GSKCH) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

High Management Efficiency with a high ROE of 23.57%

Company's ability to service its debt is strong with a healthy EBIT to Interest (avg) ratio of 36.20

The company has declared Positive results for the last 7 consecutive quarters

With ROE of 45.6, it has a attractive valuation with a 7.3 Price to Book Value

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

PKR 96,843 Million (Large Cap)

P/E

19.00

Industry P/E

Dividend Yield

3.63%

Debt Equity

-0.43

Return on Equity

43.68%

Price to Book

7.10

Revenue and Profits:

Net Sales:

10,030 Million

(Quarterly Results - Mar 2025)

Net Profit:

1,348 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-8.62%

6 Months

-18.41%

1 Year

160.18%

2 Years

421.95%

3 Years

208.05%

4 Years

168.59%

5 Years

166.61%

Haleon Pakistan Ltd. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

17.13%

EBIT Growth (5y)

36.74%

EBIT to Interest (avg)

36.20

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.70

Sales to Capital Employed (avg)

3.45

Tax Ratio

39.17%

Dividend Payout Ratio

51.14%

Pledged Shares

Institutional Holding

ROCE (avg)

87.68%

ROE (avg)

23.57%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

8.30

EV to EBIT

11.22

EV to EBITDA

10.56

EV to Capital Employed

17.05

EV to Sales

2.49

PEG Ratio

0.16

Dividend Yield

3.20%

ROCE (Latest)

152.02%

ROE (Latest)

42.99%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

Mildly Bullish

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is 3.48% vs -0.63% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2025 is -2.04% vs 3.45% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "10,029.80",
          "val2": "9,692.60",
          "chgp": "3.48%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "2,268.50",
          "val2": "2,183.30",
          "chgp": "3.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "12.70",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,347.60",
          "val2": "1,375.70",
          "chgp": "-2.04%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "211.90%",
          "val2": "210.40%",
          "chgp": "0.15%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 17.70% vs 14.91% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 359.84% vs 205.96% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "37,205.90",
          "val2": "31,609.80",
          "chgp": "17.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "7,317.00",
          "val2": "1,976.00",
          "chgp": "270.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "51.50",
          "val2": "37.80",
          "chgp": "36.24%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "4,578.20",
          "val2": "995.60",
          "chgp": "359.84%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "182.20%",
          "val2": "48.80%",
          "chgp": "13.34%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ

Mar'25

Dec'24

Change(%)

Net Sales

10,029.80

9,692.60

3.48%

Operating Profit (PBDIT) excl Other Income

2,268.50

2,183.30

3.90%

Interest

12.70

0.00

Exceptional Items

0.00

Consolidate Net Profit

1,347.60

1,375.70

-2.04%

Operating Profit Margin (Excl OI)

211.90%

210.40%

0.15%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Mar 2025 is 3.48% vs -0.63% in Dec 2024

Consolidated Net Profit

QoQ Growth in quarter ended Mar 2025 is -2.04% vs 3.45% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

37,205.90

31,609.80

17.70%

Operating Profit (PBDIT) excl Other Income

7,317.00

1,976.00

270.29%

Interest

51.50

37.80

36.24%

Exceptional Items

0.00

Consolidate Net Profit

4,578.20

995.60

359.84%

Operating Profit Margin (Excl OI)

182.20%

48.80%

13.34%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 17.70% vs 14.91% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 359.84% vs 205.96% in Dec 2023

All Annual Results

Company CV

About Haleon Pakistan Ltd.

Haleon Pakistan Ltd.

Pharmaceuticals & Biotechnology

Glaxosmithkline Consumer Healthcare Pakistan Limited is a Pakistan-based pharmaceutical company, which provides patient-focused medical solutions. It is engaged in manufacturing and marketing of research based ethical specialties, other pharmaceutical and consumer products. Its segments include Pharmaceuticals and Consumer Healthcare. Its Pharmaceuticals segment includes prescription drugs and vaccines, and consumer healthcare segment includes over-the-counter-medicines, oral care and nutritional care. It deals in Antiinfective, Respiratory, Vaccines, Dermatological, Gastrointestinal, Analgesics, Urology, Central Nervous System, Allergy, Cardiovascular and Vitamins therapy areas. Its pharmaceutical brands include Augmentin, Seretide, Amoxil, Velosef, Zantac and Calpol, and consumer healthcare brands include Panadol, Horlicks, Sensodyne and ENO. Its Global Manufacturing Services in Pakistan consists of three facilities, including West Wharf, F-268 site and Korangi.

Company Coordinates

Company Details

Sykes Building 35-Dockyard Road,, West Wharf KARACHI None : 74000

Tel: 92 21 111475725

http://pk.gsk.com/

Registrar Details